Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
Just Published
Long-term treatment with the investigational oral therapy soticlestat (OV935/TAK-935) can reduce the median seizure frequency by up to 90% in adults with Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies (DEE), according to data from the ENDYMION Phase 2 trial. Topline results are expected in the…
Recent
- Taking Time to Acknowledge Our Efforts as Parents and Caregivers
- Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients
- Brian Is a Happy Little Man
- Pandemic Won’t Stop Rare Disease Day on Feb. 28
- I’m Ready to Embrace My Emotions as an LGS Caregiver
- International Epilepsy Day Shines Spotlight on Brain Disorder Affecting Millions
- NORD’s 6th ‘State Report Card’ Notes Progress, Raises Concerns
- Jazz Acquires GW Pharma and Epidiolex, Other Potential Cannabinoids
- Study Reveals Molecular Details of Epidiolex Action
- This Is Why I Had to Sign Off